Pembrolizumab and Chemotherapy Combo Emerges for Patients With TNBCDecember 31st 2020
Earlier in the year, Javier Cortes, MD, PhD, presented progression-free survival results from the phase 3 KEYNOTE-355 clinical trial, which showed the importance of the addition of taxanes to a platinum-based regimen in the triple-negative breast cancer space.
Novel CDK4/6 Inhibitor Combos Shape Future for HR+/HER2– Breast CancerDecember 30th 2020
Despite the success of CDK4/6 inhibitors in patients with advanced hormone receptor–positive, HER2-negative breast cancer, acquired resistance develops in many. For these patients, research indicates that treatment sequencing may soon include agents that act on implicated pathways of resistance.
Venetoclax Makes Inroads Into More Hematologic SettingDecember 30th 2020
Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.
Frontline Maintenance Therapy for Urothelial Cancer EmergesDecember 30th 2020
After decades of dormancy, the therapeutic landscape of locally advanced/metastatic urothelial cancer underwent a paradigm shift—with multiple regulatory approvals of immune checkpoint inhibitors as second-line treatment—leading to changes in guideline-recommended management of patients in this setting.
RET, MET Inhibitors Advance Targeted Therapies in NSCLCDecember 28th 2020
FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.
COVID-19 and Stay-at-Home Orders Propel the Use of TelemedicineDecember 27th 2020
Response from oncologists and other clinicians who participated in a series of online educational seminars and Twitter polls showed that the conversion of follow-up visits to telemedicine for patients with lung cancer continues to expand, mainly due to effects of the COVID-19 pandemic.
Immunotherapy Approval in TMB-High Tumors Makes it More Accessible, Yet Questions RemainDecember 27th 2020
Although the use of TMB as a biomarker has been established in certain tumors, such as non–small cell lung cancer, the pan-cancer approval came as a surprise to some in the oncology community.
CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy IndicationsDecember 26th 2020
Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.
Changes in Biologics Dosing May Help Keep Patients Safe From COVID-19December 22nd 2020
Since the start of the COVID-19 pandemic, visits to doctor’s offices and infusion centers dramatically declined in an attempt to reduce patient exposure to the virus, which led to delays in the delivery of certain therapies in the oncology setting.